URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol

• Conditions: Glioblastoma

• Registration Number: NCT00392548
• Lead Sponsor: Tel-Aviv Sourasky Medical Center

Brief Summary

Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.

Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.

Detailed Description

Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment

Study Timeline

• Status Verified: 2006-09
• Study Start: 2006-10
• Study Completion: 2006-10
• Study First Submitted: 2006-10-25
• Study First Submitted QC: 2006-10-25
• Last Update Submitted: 2006-10-25
• Study First Posted: 2006-10-26
• Last Update Posted: 2006-10-26

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
• Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
• Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.

Exclusion Criteria

• Patient not able to receive 6000 cGy of radiation therapy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

tel Aviv Sourasky Medical Center; 🇮🇱 Tel Aviv, Israel